M
Maribel Rodriguez-Torres
Researcher at San Juan Bautista School of Medicine
Publications - 138
Citations - 13678
Maribel Rodriguez-Torres is an academic researcher from San Juan Bautista School of Medicine. The author has contributed to research in topics: Ribavirin & Hepatitis C. The author has an hindex of 44, co-authored 137 publications receiving 13171 citations. Previous affiliations of Maribel Rodriguez-Torres include Consejo Nacional de Ciencia y Tecnología & Pontifical Catholic University of Puerto Rico.
Papers
More filters
Journal ArticleDOI
O322: Sofosbuvir and ribavirin therapy for the treatment of HIV/HCV co-infected patients with HCV GT1-4 infection: the PHOTON-1 and -2 Trials
Jorge L. Santana,Juergen K. Rockstroh,Massimo Puoti,Maribel Rodriguez-Torres,Douglas T. Dieterich,Anuj Gaggar,Liyun Ni,Benedetta Massetto,Evguenia S. Svarovskaia,Diana M. Brainard,Mani Subramanian,John G. McHutchison,Susanna Naggie,Chloe Orkin,Jean-Michel Molina,Mark S. Sulkowski +15 more
Journal ArticleDOI
Double-blind pilot study of mesalamine vs. placebo for treatment of chronic diarrhea and nonspecific colitis in immunocompetent HIV patients.
Maribel Rodriguez-Torres,Jose F. Rodríguez-Orengo,Carlos F. Ríos-Bedoya,Alberto Fernández-Carbia,Rosa Salgado-Mercado,Acisclo M. Marxuach-Cuétara +5 more
TL;DR: Mesalamine was effective for treatment of chronic diarrhea and moderate nonspecific colitis in HIV patients and major improvements were documented in the mesalamine group at week 6 compared to baseline for all variables, whereas the placebo group did not have any.
Journal ArticleDOI
60 results of enable 2, a phase 3, multicenter study of eltrombopag and peginterferon alfa-2b treatment in patients with hepatitis c and thrombocytopenia
G.M. Dusheiko,Nezam H. Afdhal,Edoardo G. Giannini,Pei-Jer Chen,K.-H. Han,Maribel Rodriguez-Torres,Sorin Rugină,E.J. Lawitz,A. Streinu-Cercel,Mitchell L. Shiffman,Fred Poordad,Y. Mostafa Kamel,Andres Brainsky,James Geib,Sandra Y. Vasey,Rita Patwardhan,Fiona Campbell,Dickens Theodore +17 more
Journal ArticleDOI
Degree of viral decline early in treatment predicts sustained virological response in HCV-HIV coinfected patients treated with peginterferon alfa-2a and ribavirin.
Maribel Rodriguez-Torres,Francesca J. Torriani,Juergen K. Rockstroh,Jean DePamphilis,Giampiero Carosi,Douglas T. Dieterich +5 more
TL;DR: A rapid virological response is the best predictor of a sustained virol logical response, and lack of an early virology response isThe best predictors of no sustained virologic response.
Journal ArticleDOI
In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions.
Alessandra Mangia,Tivadar Bányai,Giuseppe G. De Bartolomeo,Judit Gervain,François Habersetzer,Jean-Pierre Mulkay,Denis Ouzan,Giustino G. Parruti,Nicola Passariello,Andre Jean A.J. Remy,Mario Rizzetto,Mitchell L. Shiffman,Alan Douglas A.D. Tice,Manuela Schmitz,Fernando Tatsch,Maribel Rodriguez-Torres +15 more
TL;DR: This subanalysis assesses rates of premature treatment discontinuation stratified by on‐treatment virological response (VR) in chronic hepatitis C patients treated with peginterferon alfa/ribavirin.